Axon Enterprise, Inc. NASDAQ: AXON

What we're investigating

Henzel Law is investigating potential securities fraud claims on behalf of shareholders of Axon Enterprise, Inc. (NASDAQ: AXON), which supplies conducted energy weapons, body cameras, software and counter-drone systems to public safety agencies. The investigation concerns whether the Company and certain of its officers made materially misleading statements about the adoption of its counter-drone products and the achievability of its 2026 revenue guidance. No lawsuit has been filed yet in this matter.

Background

On August 5, 2026, announcing second-quarter results, Axon raised its full-year revenue growth guidance to 32% to 34%, up 200 basis points from a prior range of 30% to 32%. On the same call, management said the Company continued to “see strong demand across customer markets,” that its Dedrone counter-drone business was “delivering tremendous growth,” and that it “certainly expect[ed] the Dedrone demand to endure.”

On September 15, 2026, Axon launched a registered offering of 0% convertible senior notes off an effective shelf registration statement. The offering closed on September 18, 2026 at $1.15 billion, including the full exercise of the underwriters' option. The prospectus supplement stated that the Company “continued to see strong adoption of its AI and counter-drone offerings.”

What happened on November 5 and 6, 2026

After the market closed on November 5, 2026, Axon reported third-quarter revenue of approximately $909 million, up 28%, and cut its full-year revenue growth guidance to approximately 30% — roughly $3.61 billion to $3.63 billion, below the range its August guidance had implied. Full-year free cash flow guidance was also cut, to $350–$400 million from a prior $450 million target.

Management attributed the revision to three delayed federal counter-drone deployments representing approximately $130 million of expected revenue and approximately $200 million of bookings. One $30 million deployment had been expected in the third quarter; two more, totaling roughly $100 million, had been forecast for the fourth. Management said the delays reflected slower federal procurement tied to funding and election cycles, and that the Company could not be sure the deployments would close in 2026.

On November 6, 2026, Axon's share price fell approximately 18.2% to close at $313.00, a 52-week low.

What the investigation is examining

The question is what the Company knew about the status of those three federal deployments when it raised guidance on August 5 and when it marketed the note offering in September. Management has not said when it learned of the delays, and no analyst asked.

The September offering warrants separate attention. Because it was a registered offering made under a prospectus supplement rather than a private placement, claims under the Securities Act of 1933 may be available to purchasers in that offering — a path that does not require proof of intent. The statement that the Company “continued to see strong adoption of its AI and counter-drone offerings” is the natural focus.

Several facts cut the other way and are part of the inquiry. On the same August call, management cautioned that large hardware shipments “can swing a little” quarter to quarter, and the Company's standing disclosures warn about government funding and appropriations. Management has also characterized the deployments as delayed rather than lost, saying they would be treated as upside if they close. And the November 5 announcement included other unfavorable news — the free cash flow cut and a $1.2 billion investment in another company — which complicates attributing the whole decline to the counter-drone disclosure.